Filing Flows

Filing Flows › Companies › Prelude Therapeutics › Cash flow

Prelude Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$15.6M in Q2 2026 · −$33.3M over twelve months

Operating cash flow−$15.6M
Free cash flow−$15.6M

Analysis

In Q2 2026, Prelude Therapeutics generated −$15.6M of operating cash flow. That is $10.5M more than in Q2 2025 (−$26.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$33.3M; the largest uses were other investing ($77.3M), operating cash flow ($33.3M), taxes on employees’ shares ($74K); besides operations, cash came from other financing ($110M), shares issued ($132K); the cash balance fell by $62K.

Operating cash flow was −$15.6M against net income of −$13.9M. The largest differences: deferred revenue −$5.7M, stock-based pay +$2.0M, accrued liabilities +$1.9M.

Free cash flow

Prelude Therapeutics: free cash flow by quarterPrelude Therapeutics: free cash flow by quarter−$27.4MQ3 2024−$20.8MQ4 2024−$34.3MQ1 2025−$26.1MQ2 2025−$19.1MQ3 2025$23.1MQ4 2025−$21.7MQ1 2026−$15.6MQ2 2026
Operating cash flow less capital spending.
Prelude Therapeutics: operating cash flow against capital spendingPrelude Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$27.3M$63KQ3 2024−$20.7M$53KQ4 2024−$34.2M$47KQ1 2025−$26.1M$20KQ2 2025−$19.1M$0Q3 2025$23.1M$0Q4 2025−$21.7M$0Q1 2026−$15.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$15.6M, Capital spending $0.

Capital allocation, year by year

Prelude Therapeutics: where the cash came from (up) and went (down), by fiscal yearPrelude Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$83.5MFY2021: Shares issued $165MFY2021: Capital spending −$2.3M$165MFY2021FY2022: Operating cash flow −$83.7MFY2022: Shares issued $389KFY2022: Capital spending −$3.0M$389KFY2022FY2023: Operating cash flow −$107MFY2023: Shares issued $47KFY2023: Capital spending −$3.5M$47KFY2023FY2024: Operating cash flow −$103MFY2024: Net borrowing −$395KFY2024: Shares issued $60KFY2024: Capital spending −$764K$60KFY2024FY2025: Operating cash flow −$56.3MFY2025: Net borrowing −$208KFY2025: Shares issued $16KFY2025: Capital spending −$67K$16KFY2025
Over these 5 years operating cash flow totalled −$434M; the largest uses were operating cash flow ($434M) and capital spending ($9.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$152M
Debtnone
Net cash$152M
Cash runway4.6 years

Prelude Therapeutics is burning cash: its operations consume cash, a free cash flow of −$33.3M a year at the current rate against $152M of cash and investments: a runway of about 4.6 years before any new financing.

Where the cash came from and went

Prelude Therapeutics: sources (+) and uses (−) of cash, Q2 2026Prelude Therapeutics: sources (+) and uses (−) of cash, Q2 2026Other financing$85.7MOther investing−$65.5MOperating cash flow−$15.6MCash drawn (+) / kept (−)−$4.7MShares issued$85KTaxes on employees’ shares−$13K
Prelude Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Prelude Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$110MOther investing−$77.3MOperating cash flow−$33.3MShares issued$132KTaxes on employees’ shares−$74KCash drawn (+) / kept (−)$62K

From profit to cash

Prelude Therapeutics: net income to operating cash flow, Q2 2026Prelude Therapeutics: net income to operating cash flow, Q2 2026Net income−$13.9MDepreciation & amortization$353KStock-based pay$2.0MPayables−$154KAccrued liabilities$1.9MDeferred revenue−$5.7MPrepaid and other assets−$102KOperating cash flow−$15.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$15.6M——$85K−$4.7M−$15.6M
Q1 2026−$21.7M——$31K$13.5M−$21.7M
Q4 2025$23.1M——$16K$12.3M$23.1M
Q3 2025−$19.1M———−$21.0M−$19.1M
Q2 2025−$26.1M−$20K−$53K—$14.5M−$26.1M
Q1 2025−$34.2M−$47K−$155K—−$27.8M−$34.3M
Q4 2024−$20.7M−$53K−$151K—−$1.3M−$20.8M
Q3 2024−$27.3M−$63K−$148K$56K$16.7M−$27.4M

Prelude Therapeutics: income statement and cash flow

Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%. The chart follows the revenue to costs, profit and cash.

Prelude Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.